Antiplatelet Medications in Hemodialysis Patients
- 1 August 2009
- journal article
- review article
- Published by Ovid Technologies (Wolters Kluwer Health) in Clinical Journal of the American Society of Nephrology
- Vol. 4 (8), 1347-1355
- https://doi.org/10.2215/cjn.00810209
Abstract
Background and objectives: Patients with end stage renal disease (ESRD) are often prescribed antiplatelet medications. However, these patients are also at increased risk of bleeding compared with the general population, and an aim was made to quantify this risk with antiplatelet agents. Design, setting, participants, & measurements: A systematic review of the literature (Medline, EMBASE, Cochrane CENTRAL and Google Scholar databases) was done to determine the bleeding risk in ESRD patients prescribed antiplatelet therapy. The secondary outcome was the effect on access thrombosis. All case series, cohort studies and clinical trials were considered if they included ten or more ESRD patients, assessed bleeding risk with antiplatelet agents, and lasted for more than 3 mo. Results: Sixteen studies, including 40,676 patients, were identified that met predefined inclusion criteria. Due to study heterogeneity and weaknesses in methodology, bleeding rates were not pooled across studies. However, the bleeding risk appears to be increased for hemodialysis patients treated with combination antiplatelet therapy. The results are mixed for studies using a single antiplatelet agent. Antiplatelet agents appear to be effective in preventing shunt and central venous catheter thrombosis, but not for preventing thrombosis of arteriovenous grafts. Conclusion: The risks and benefits of antiplatelet agents in ESRD patients remain poorly defined. Until a clinical trial addresses this in the dialysis population, individual risk stratification taking into account the increased risk of bleeding should be considered before initiating antiplatelet agents, especially in combination therapy.This publication has 45 references indexed in Scilit:
- Anticoagulant and Antiplatelet Usage Associates with Mortality among Hemodialysis PatientsJournal of the American Society of Nephrology, 2009
- Hemoglobin Targets and Blood Transfusions in Hemodialysis Patients without Symptomatic Cardiac Disease Receiving Erythropoietin TherapyClinical Journal of the American Society of Nephrology, 2008
- Consistent Aspirin Use Associated with Improved Arteriovenous Fistula Survival among Incident Hemodialysis Patients in the Dialysis Outcomes and Practice Patterns StudyClinical Journal of the American Society of Nephrology, 2008
- The efficacy and safety of short- and long-term dual antiplatelet therapy in patients with mild or moderate chronic kidney disease: Results from the Clopidogrel for the Reduction of Events During Observation (CREDO) TrialAmerican Heart Journal, 2008
- Major Bleeding in Hemodialysis PatientsClinical Journal of the American Society of Nephrology, 2008
- The way I see it: House officers need formal career developmentBMJ, 2002
- Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patientsBMJ, 2002
- Assessing the quality of reports of randomized clinical trials: Is blinding necessary?Controlled Clinical Trials, 1996
- Prevention of Thrombosis in Patients on Hemodialysis by Low-Dose AspirinThe New England Journal of Medicine, 1979
- The role of sulfinpyrazone in the prevention of arterio-venous shunt thrombosis.Circulation, 1975